ELGIN, Ill., April 4, 2016 /PRNewswire/ – Royal DSM, a global science-based company active in health, nutrition and materials, announces that its Somos® business, a world leader in Additive Manufacturing materials, has moved into a beta phase for its collaborative program with EnvisionTEC, a world leader in professional grade 3D Printing equipment.
Somos® and EnvisionTEC are working closely to develop game-changing solutions for the 3SP® series of large frame 3D printers offered by EnvisionTEC. Excellent results have been achieved in the alpha testing phase for a new, high-performance material designed to be durable with high-detail resolution and dimensional stability. The next step will involve the beta testing of this material with one of EnvisionTEC’s key customers.
“Great progress has been made in the collaborative partnership with Somos®,” says John Hartner, Chief Operating Officer EnvisionTEC. “We are excited to test this developmental material with one of our strategic customers that is looking to make very large parts with high detail. We believe they will be as excited as we are with the performance of the 3SP® printer and this material.”
“This is just the start of the collaboration between us,” says Melissa Lutz, Business Director Somos®. “We are thrilled to be working with EnvisionTEC to bring new solutions to the 3D printing industry.”
DSM – Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com.
About Somos®
DSM believes that 3D printing is a major change agent for the world creating brighter lives for people today and generations to come. Somos®, a product brand of DSM, moves the Additive Manufacturing industry to a new level of performance. We are dedicated to helping our customers grow in the ever-changing world of 3D Printing and promote this growth through continuous material and application development, encouraging industry collaboration and maximizing customer asset value by providing continuous information and support. More information about Somos® can be found at www.dsm.com/somos.
About EnvisionTEC
EnvisionTEC is a leading global provider of professional grade 3D printing solutions for the rapid manufacture of customized products utilizing its proprietary consumables across a variety of markets. Since its first patent submission in 1999, EnvisionTEC has developed and released 3D print solutions consisting of 3D printers, print materials and replacement parts, as well as training and other services. Their proprietary, multi-platform technology delivers high precision, speed, surface quality and functionality and uses a wide range of materials at high production speeds. EnvisionTEC works with a strong customer and partner bases in diverse sectors, including jewelry, hearing aids, dental, consumer, auto manufacturing and design companies. For more information, please visit envisiontec.com.
For more information: DSM Functional Materials
Kelly Hawkinson
Global Marketing & Communications Director
Tel. +1-847-608-2530
kelly.hawkinson@dsm.com
Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
Source: DSM